Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$2.3 million.

  • Compass Therapeutics' Change in Accured Expenses rose 4646.25% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 31143.7%. This contributed to the annual value of $3.8 million for FY2024, which is 14111.81% up from last year.
  • Compass Therapeutics' Change in Accured Expenses amounted to -$2.3 million in Q3 2025, which was up 4646.25% from -$2.2 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Change in Accured Expenses high stood at $6.9 million for Q1 2025, and its period low was -$4.3 million during Q3 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$2.2 million (2023), whereas its average is -$273272.7.
  • The largest annual percentage gain for Compass Therapeutics' Change in Accured Expenses in the last 5 years was 109098.71% (2025), contrasted with its biggest fall of 14105.69% (2025).
  • Compass Therapeutics' Change in Accured Expenses (Quarter) stood at -$3.1 million in 2023, then soared by 207.7% to $3.4 million in 2024, then crashed by 168.47% to -$2.3 million in 2025.
  • Its Change in Accured Expenses was -$2.3 million in Q3 2025, compared to -$2.2 million in Q2 2025 and $6.9 million in Q1 2025.